MapLight Therapeutics Inc
MPLTHealthcare|Biotechnology|USA
$39.28
-0.48 (-1.21%)
Tangible Book
$8.84
Clinical Trials (6)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07459660 An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis | Psychosis Associated With Alzheimer's Disease | P2 | Recruiting | 210 | Open-label | ML-007C-MA |
| NCT06887192 A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis | Psychosis Associated With Alzheimer's Disease | P2 | Recruiting | 300 | RCT, Double-blind | ML-007C-MA, Placebo |
| NCT07459647 A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia | Schizophrenia | P2 | Recruiting | 500 | Open-label | ML-007C-MA |
| NCT05889273 ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD) | Autism Spectrum Disorder | P2 | By Invite | 120 | Open-label | ML-004 (IR)/(ER) tablet |
| NCT07038876 A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia | Schizophrenia | P2 | Completed | 307 | RCT, Double-blind | Placebo, ML-007C-MA BID, ML-007C-MA QD |
| NCT05081245 ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD) | Autism Spectrum Disorder | P2 | Completed | 168 | RCT, Double-blind | ML-004 (IR)/(ER) tablet, ML-004 Placebo |